Alychlo is the family investment company of Belgian entrepreneur Marc Coucke, founded in 2015. It invests in growth-stage companies across healthcare, technology, real estate, and consumer sectors, providing active strategic and operational support to management.
38% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $69.2M (across 4 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Unknown
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aikido | Series B | $60M | Jan 2026 |
| BBanqup Group | Unknown | — | Jan 2026 |
 Sophia Genetics | Series F | $110M | Oct 2020 |
 miDiagnostics | Series D | — | Jan 2020 |
| Sophia Genetics | Series E | $77M | Jan 2019 |
| Sophia Genetics | Series D | $30M | Sep 2017 |
 ITINERIS | Unknown | — | Jan 2017 |
| LLizy | Unknown | — | — |
Top Co-Investors
Eurazeo2 shared
Balderton Capital2 shared
360 Capital Partners1 shared
INKEF Capital1 shared
aMoon1 shared
ACE & Company1 shared
Hitachi Ventures1 shared
Credit Suisse Group AG1 shared
Swisscom Ventures1 shared
Allen & Company LLC1 shared
Endeavour Vision1 shared
Idinvest Partners1 shared
SFPIM Relaunch1 shared
Smartfin1 shared
Gimv1 shared
existing shareholders1 shared
PMV1 shared
European Investment Bank1 shared
DST Global1 shared
Last updated: 20 October 2026